Data completeness
0/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUDAFED 12 HOUR is an extended-release oral capsule decongestant in pre-launch development by GSK. The product mechanism of action and specific indications are not yet disclosed, but based on the SUDAFED brand portfolio, it likely treats nasal congestion and related cold/allergy symptoms. As a small-molecule extended-release formulation, it offers prolonged symptom relief compared to immediate-release alternatives.
Pre-Launch
Pre-launch stage indicates active recruitment for brand, medical, and commercial teams preparing for market entry and competitive positioning in the OTC decongestant category.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SUDAFED 12 HOUR pre-launch status creates immediate career opportunities in commercial launch planning, brand building, and field execution within GSK's Consumer Healthcare division. Roles focus on market entry strategy, pharmacy relationships, and consumer awareness in the competitive OTC decongestant space.
Brand ManagerProduct Manager
Worked on SUDAFED 12 HOUR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.